Transscleral diode laser cyclophotocoagulation (CPC) has been established as long-term, effective intraocular pressure (IOP) lowering procedure for many types of glaucoma patients. It has become a popular alternative to surgical practices for refractory glaucoma. The surgery can be done before and after any other surgery, such as metabolite augmented trabeculectomy or viscocanalostomy. This makes it a very versatile procedure from which patients with refractory glaucoma and those with good visual acuity can benefit from.
Transscleral cyclophotocoagulation
The wavelength of 810 nm allows a safer treatment compared to other methods of cyclophotocoagulation or cyclocryotherapy, reducing the risk of hypotony and
phthisis. Using a specially designed probe, the laser beam passes the sclera and is absorbed by the ciliary body, which in turn results in coagulation. The sclera is not affected. The destruction of the ciliary body leads to significant reduction of the IOP. The treatment requires only local anesthetics and will be performed as an outpatient procedure.